Biomea Fusion Presents Novel Preclinical Data at ADA 2022 Suggesting BMF-219’s Potential as an Oral, Long-Acting Treatment for Type 2 Diabetes
Menin acts as a ‘brake’ on beta cell regeneration; inhibiting menin function with BMF-219 may increase beta cell production and...